Proteome Sciences’ proprietary TMTcalibrator™ workflow for tissue-enhanced phosphoproteomics in Alzheimer’s disease CSF featured in new publication from Cognition Therapeutics, Inc. Results show that CT1812 treatment reduces levels of phosphorylation on CSF tau including at many sites only quantifiable using TMTcalibrator™. Citation: “Izzo NJ, Yuede CM, LaBarbera KM, et al. Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer’s disease modification. Alzheimer’s Dement. 2021;1-18. https://doi.org/10.1002/alz.